Table 1

Baseline characteristics and workflow processes in patients with M2 segment MCA occlusions in endovascular therapy (EVT) and control groups

CharacteristicEndovascular treatment group
Mean±SD (n=67)
[Median] (IQR)
Control group
Mean±SD (n=64*)
[Median] (IQR)
P value
Age (years)66.0±13.7 (67)
[66.4] (56.9,76.0)
65.2±12.0 (64)
[65.9] (57.9,75.0)
0.71
Sex (female, %)53.7% (36/67)46.9% (30/64)0.49
History of hypertension (%)61.2% (41/67)59.4% (38/64)0.86
History of dyslipidemia (%)36.9% (24/65)35.9% (23/64)1.00
History of diabetes mellitus (%)16.4% (11/67)21.9% (14/64)0.51
Atrial fibrillation (%)38.1% (24/63)28.3% (17/60)0.34
NIHSS at baseline14.4±5.1 (67)
[14.0] (11.0,19.0)
15.4±6.0 (63)
[15.0] (11.0,20.0)
0.32
Baseline non-contrast CT ASPECTS8.6±1.4 (67)
[9.0] (8.0,10.0)
8.1±1.6 (64)
[8.0] (7.0,10.0)
0.06
Intravenous alteplase administered85.1% (57/67)89.1% (57/64)0.61
Stroke onset to intravenous alteplase bolus (min)119.6±54.3 (56) [107.5] (83.8,136.3)113.5±44.8 (57) [100.0] (84.0,140.0)0.52
Stroke onset to randomization (min)199.5±84.1 (67) [180.0] (147.5,250.5)209.0±76.5 (63) [193.0] (152.5,264.0)0.50
Stroke onset to groin puncture (min)238.2±90.3 (61) [220.0] (90.0,599.0)
  • *One patient with missing 90-day outcome was excluded from the outcome analysis.

  • ASPECTS, Alberta Stroke Programme Early CT Score; NIHSS, National Institute of Health Stroke Score.